We report a 69-year-old female with erythroblastopenia and thymoma who developed lesions of Kaposi’s sarcoma (KS) after thymectomy, 2 months after the initiation of therapy with methylprednisolone. Control of mucocutaneous KS lesions was obtained with radiotherapy, interferon alfa-2b and withdrawal of systemic immunosuppressive therapy. Erosive oral lichen planus appeared later, and after therapy with topical corticosteroids a new lesion of KS developed that regressed after withdrawal of topical corticosteroids. The detection of HHV-8 only in lesional skin supports the hypothesis that this virus can trigger the development of KS lesions.

Keywords:
Kaposi’s sarcoma, Female, Erythroblastopenia, Thymoma, Corticosteroids, HHV-8
1.
Fife K, Bower M: Recent insights into the pathogenesis of Kaposi’s sarcoma. Br J Cancer 1996;73:1317–1322.
2.
Simon M, Kind P, Kaudewitz P, Graf A, Schirren CG, Raffeld M, Sander CA: Detection of herpesvirus-like DNA in HIV-associated and classial Kaposi’s sarcoma. Arch Dermatol Res 1996;288:402–404.
3.
Safai B, Miké V, Giraldo G, Beth E, Good RA: Association of Kaposi’s sarcoma with second primary malignancies: Possible etiopathogenic implications. Cancer 1980;45:1472–1479.
4.
Reynolds WA, Winkelmann RK, Soule EH: Kaposi’s sarcoma: A clinicopathologic study with particular reference to its relationship to the reticuloendothelial system. Medicine (Baltimore) 1965;44:419–443.
5.
Gellin GA: Kaposi’s sarcoma: Three cases of which two have unusual findings in association. Arch Dermatol 1966;94:92–94.
6.
Maberry JD, Stone OJ: Kaposi’s sarcoma with thymoma. Arch Dermatol 1967;95:210–213.
7.
Souadjian JV, Silverstein MN, Titus JL: Thymoma and cancer. Cancer 1968;22:1221–1225.
8.
Val-Bernal JF, Palacios S, Rodríguez Castro J: Timoma y sarcoma de Kaposi. Patología 1980; 13:253–259.
9.
Ulbright TM, Santa Cruz DJ: Kaposi’s sarcoma: Relationship with hematologic, lymphoid, and thymic neoplasia. Cancer 1981; 47:963–973.
10.
Snyder RA, Schwartz RA: Telangiectatic Kaposi’s sarcoma. Occurrence in a patient with thymoma and myasthenia gravis receiving long-term immunosuppressive therapy. Arch Dermatol 1982;118:1020–1021.
11.
Alcoba Leza M, Cabreros Pisonero E, Menéndez Gutiérrez ML: Sarcoma de Kaposi como segunda neoplasia en el timoma. Rev Clín Esp 1987;180:520–521.
12.
Sawai T, Tuchikawa K: Kaposi’s sarcoma developed in a patient with a thymoma in the setting of excess numbers of CD-8 positive cells in the peripheral blood. Arch Pathol Lab Med 1990;114:611–613.
13.
Moysset I, Lloreda J, Miguel A, Vadell C, Ribalta T, Estrach T, Serrano S: Thymoma associated with CD4+ lymphopenia, cytomegalovirus infection, and Kaposi’s sarcoma. Hum Pathol 1997;28:1211–1213.
14.
Trattner A, Hodak E, David M, Sandbank M: The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993;72: 1779–1783.
15.
Amblard P, Reymond JL, Sotto JJ, Couderc P: Maladie de Kaposi au cours des états dysimmunitaires. Nouv Presse Méd 1978;7: 122–123.
16.
Casoli P, Tumiati B: Rheumatoid arthritis, corticosteroids therapy and Kaposi’s sarcoma: A coincidence? A case and review of literature. Clin Rheumatol 1992;11:432–435.
17.
Hortelano E, Calvo J, Liñana JJ, González-Cruz MI, Soler JJ, Fontbuena M: Sarcoma de Kaposi visceral y cutáneo en paciente con artritis reumatoide en tratamiento esteroideo. An Med Intern 1994;11:77–79.
18.
Carmeli Y, Mevorach D, Kaminski N, Raz E: Regression of Kaposi’s sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 1994;73:2859–2861.
19.
Casoli P, Tumiati B: Kaposi’s sarcoma, rheumatoid artritis and immunosuppressive and/or corticosteroid therapy. J Rheumatol 1992;19:1316–1317.
20.
Abel EA: Cutaneous manifestations of immunosuppression in organ transplant recipients. J Am Acad Dermatol 1989;21:167–179.
21.
Nikkels AF, Collignon J, Moutschen MP, Paquet P, Bouillenne C, Piérard GE: Maladie de Kaposi chez une patiente souffrant d’une immunodéficience acquise VIH négative. Presse Méd 1994;23:1760–1761.
22.
Bruet A, Mahe A, Sei JF, Mathe C, Felsenheld C, Lechevalier L, Fendler JP: Sarcome de Kaposi compliquant une corticothérapie au long cours pour asthme sévère. Rev Méd Interne 1990;11:322–324.
23.
Krussmann A, Goerg R, Laberke HG, Weidner FO: Ausgedehnt metastasiertes Kaposi-Sarkom bei chronisch immunsupprimiertem Bronchialasthma. Hautarzt 1993;44:232–234.
24.
Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866–869.
25.
Corda L, Benerecetti D, Ungari M, Facchetti F, Rafaeli E: Kaposi’s disease and sarcoidosis. Eur Respir J 1996;9:383–385.
26.
Barreca T, Corsini G, Franceschini R, Gambini C, Garibaldi A, Rolandi E: Lichen planus induced by interferon-alpha-2a therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol 1995;7:367–368.
27.
Nunez M, Miralles ES, de las Heras ME, Ledo A: Appearance of oral erosive lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. J Dermatol 1995;22: 461–462.
28.
Schlesinger TE, Camisa C, Gay JD, Bergfeld WF: Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol 1997;36: 1023–1025.
29.
Areias J, Velho GC, Cerqueira R, Barbedo C, Amaral B, Sanches M, Massa A, Saraiva AM: Lichen planus and chronic hepatitis C: Exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol 1996; 8:825–828.
30.
Heintges T, Frieling T, Goerz G, Niederau C: Exacerbation of lichen planus but not of acute intermittent hepatic porphyria during interferon therapy in a patient with chronic hepatitis C. J Hepatol 1994;21:1152–1153.
31.
Lapidoth M, Arber N, Ben-Amitai D, Hagler J: Successful interferon treatment for lichen planus associated with chronic active hepatitis due to hepatitis C virus infection. Acta Derm Venereol 1997;77:171–172.
32.
Daoud MS, Gibson LE, Daoud S, el-Azhary RA: Chronic hepatitis C and skin diseases. Mayo Clin Proc 195;70:559–564.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.